Abstract
For suicide gene therapy, initially prodrug-converting enzymes (gene-directed enzyme-producing therapy, GDEPT) were employed to intracellularly metabolize non-toxic prodrugs into toxic compounds, leading to the effective suicidal killing of the transfected tumor cells. In this regard, the suicide gene therapy has demonstrated its potential for efficient tumor eradication. Numerous suicide genes of viral or bacterial origin were isolated, characterized, and extensively tested in vitro and in vivo, demonstrating their therapeutic potential even in clinical trials to treat cancers of different entities. Apart from this, growing efforts are made to generate more targeted and more effective suicide gene systems for cancer gene therapy. In this regard, bacterial toxins are an alternative to the classical GDEPT strategy, which add to the broad spectrum of different suicide approaches. In this context, lytic bacterial toxins, such as streptolysin O (SLO) or the claudin-targeted Clostridium perfringens enterotoxin (CPE) represent attractive new types of suicide oncoleaking genes. They permit as pore-forming proteins rapid and also selective toxicity toward a broad range of cancers. In this chapter, we describe the generation and use of SLO as well as of CPE-based gene therapies for the effective tumor cell eradication as promising, novel suicide gene approach particularly for treatment of therapy refractory tumors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amit D, Hochberg A (2012) Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. Int J Clin Exp Med 5:296–305
Amit D, Tamir S, Hochberg A (2013) Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences. Int J Clin Exp Med 6:110–118. doi:10.1186/1479-5876-8-134
Bhakdi S, Bayley H, Valeva A et al (1996) Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol 165:73–79. doi:10.1007/s002030050300
Briggs DC, Naylor CE, Smedley JG et al (2011) Structure of the food-poisoning Clostridium perfringens enterotoxin reveals similarity to the aerolysin-like pore-forming toxins. J Mol Biol 413:138–149. doi:10.1016/j.jmb.2011.07.066
Chakrabarti G, Zhou X, McClane BA (2003) Death pathways activated in CaCo-2 cells by Clostridium perfringens enterotoxin. Infect Immun 71:4260–4270
Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714. doi:10.1038/nrg2634
Danda R, Krishnan G, Ganapathy K et al (2013) Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy. PLoS ONE 8:e83398. doi:10.1371/journal.pone.0083398
Deng Q, Barbieri JT (2008) Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol 62:271–288. doi:10.1146/annurev.micro.62.081307.162848
Di Stasi A, Tey S-K, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673–1683. doi:10.1056/NEJMoa1106152
Dorer DE, Nettelbeck DM (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61:554–571. doi:10.1016/j.addr.2009.03.013
Felgner S, Kocijancic D, Frahm M, Weiss S (2016) Bacteria in cancer therapy: renaissance of an old concept. Int J Microbiol 2016:1–14. doi:10.1155/2016/8451728
Fidias P, Pennell NA, Boral AL et al (2009) Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol 4:1156–1162. doi:10.1097/JTO.0b013e3181b2793f
Freedman J, Shrestha A, McClane B (2016) Clostridium perfringens Enterotoxin: action, genetics, and translational applications. Toxins (Basel) 8:73. doi:10.3390/toxins8030073
Fujita K, Katahira J, Horiguchi Y et al (2000) Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 476:258–261
Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB (2004) Development of a cancer-targeted tissue-specific promoter system. Cancer Res 64:363–369. doi:10.1158/0008-5472.can-03-2507
Gao Z, McClane B a (2012) Use of Clostridium perfringens enterotoxin and the enterotoxin receptor-binding domain (C-CPE) for cancer treatment: opportunities and challenges. J Toxicol 2012:981626. doi:10.1155/2012/981626
Gillet J-P, Macadangdang B, Fathke RL et al (2009) The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol Clift NJ 542:5–54
Gofrit ON, Benjamin S, Halachmi S et al (2014) DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol 191:1697–1702. doi:10.1016/j.juro.2013.12.011
Gumbiner B (1987) Structure, biochemistry, and assembly of epithelial tight junctions. Am J Physiol 253:C749–C758
Günzel D, Fromm M (2012) Claudins and other tight junction proteins. Compr Physiol 2:1819–1852. doi:10.1002/cphy.c110045
Hanna PC, Mietzner TA, Schoolnik GK, McClane BA (1991) Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region. J Biol Chem 266:11037–11043
Hasenpusch G, Pfeifer C, Aneja MK et al (2011) Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS ONE 6:e20760. doi:10.1371/journal.pone.0020760
Haviv YS, Blackwell J (2001) Transcriptional regulation in cancer gene therapy. Isr Med Assoc J 3:517–522
Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186. doi:10.1186/1471-2407-6-186
Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288. doi:10.1038/nrc776
Johnson EA (1999) Clostridial toxins as therapeutic agents: benefits of natur's most toxic proteins. Annu Rev Microbiol 53:551–75. doi:10.1146/annurev.micro.53.1.551
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
Katahira J, Inoue N, Horiguchi Y et al (1997) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 136:1239–1247
Kawakami K, Kawakami M, Joshi BH, Puri RK (2001) Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 61:6194–6200
Kitadokoro K, Nishimura K, Kamitani S et al (2011) Crystal structure of Clostridium perfringens enterotoxin displays features of beta-pore-forming toxins. J Biol Chem 286:19549–19555. doi:10.1074/jbc.M111.228478
Kojima T, Kyuno D, Sawada N (2012) Targeting claudin-4 in human pancreatic cancer. Expert Opin Ther Targets 16:881–887. doi:10.1517/14728222.2012.708340
Kominsky SL, Tyler B, Sosnowski J et al (2007) Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 67:7977–7982. doi:10.1158/0008-5472.CAN-07-1314
Kominsky SL, Vali M, Korz D et al (2004) Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 164:1627–1633
Lal-Nag M, Battis M, Santin a D, Morin PJ (2012) Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis 1:e33. doi:10.1038/oncsis.2012.32
Litkouhi B, Kwong J, Lo C-M et al (2007) Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9:304–314
Louie GV, Yang W, Bowman ME, Choe S (1997) Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol Cell 1:67–78. doi:10.1016/S1097-2765(00)80008-8
Lu C, Stewart DJ, Lee JJ et al (2012) Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS ONE 7:e34833. doi:10.1371/journal.pone.0034833
Lu Z, Ding L, Lu Q, Chen Y-H (2013) Claudins in intestines: distribution and functional significance in health and diseases. Tissue barriers 1:e24978
Martín V, Cortés ML, de Felipe P et al (2000) Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res 60:3218–3224
Matouk I, Raveh E, Ohana P et al (2013) The increasing complexity of the oncofetal h19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci 14:4298–4316. doi:10.3390/ijms14024298
Matsuda M, Sugimoto N (1979) Calcium-independent and dependent steps in action of Clostridiumperfringens enterotoxin on HeLa and Vero cells. Biochem Biophys Res Commun 91:629–636. doi:10.1016/0006-291X(79)91568-7
Maxwell F, Maxwell IH, Glode LM (1987) Cloning, sequence determination, and expression in transfected cells of the coding sequence for the tox 176 attenuated diphtheria toxin A chain. Mol Cell Biol 7:1576–1579
Maxwell IH, Maxwell F, Glode LM (1986) Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Res 46:4660–4.
McCarthy EF (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26:154–158
Michl P, Buchholz M, Rolke M et al (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678–684. doi:10.1053/gast.2001.27124
Minton NP (2003) Clostridia in cancer therapy. Nat Rev Microbiol 1:237–242
Mizrahi A, Czerniak A, Levy T et al (2009) Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 7:69. doi:10.1186/1479-5876-7-69
Moulder SL, Symmans WF, Booser DJ et al (2008) Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14:7909–7916. doi:10.1158/1078-0432.CCR-08-1104
Neesse a, Griesmann H, Gress TM, Michl P (2012) Claudin-4 as therapeutic target in cancer. Arch Biochem Biophys 524:64–70. doi:10.1016/j.abb.2012.01.009
Pahle J, Aumann J, Kobelt D, Walther W (2015) Oncoleaking: use of the pore-forming clostridium perfringens enterotoxin (CPE) for suicide gene therapy. Methods Mol Biol 1317:69–85. doi:10.1007/978-1-4939-2727-2_5
Patyar S, Joshi R, Byrav DP et al (2010) Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 17:21
Rangel LBA, Agarwal R, D’Souza T et al (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567–2575
Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111–121. doi:10.1038/nrd726
Richardson MA, Ramirez T, Russell NC, Moye LA (1999) Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 5:42–47
Robertson SL, Smedley JG, Singh U et al (2007) Compositional and stoichiometric analysis of Clostridium perfringens enterotoxin complexes in Caco-2 cells and claudin 4 fibroblast transfectants. Cell Microbiol 9:2734–2755
Saeki R, Kondoh M, Kakutani H et al (2009) A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol 76:918–926
Santel A, Aleku M, Röder N et al (2010) Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16:5469–5480. doi:10.1158/1078-0432.CCR-10-1994
Santin AD, Bellone S, Siegel ER et al (2007) Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin Cancer Res 13:3339–3346
Saukkonen K, Hemminki A (2004) Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4:683–96
Scaiewicz V, Sorin V, Fellig Y et al (2010) Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J Oncol 2010:178174. doi:10.1155/2010/178174
Senzer N, Nemunaitis J, Nemunaitis D et al (2013) Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21:1096–1103. doi:10.1038/mt.2013.32
Sharpe M, Mount N (2015) Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech 8:337–350. doi:10.1242/dmm.018036
Shatursky O, Heuck AP, Shepard LA et al (1999) The mechanism of membrane insertion for a cholesterol-dependent cytolysin. Cell 99:293–299. doi:10.1016/S0092-8674(00)81660-8
Showalter S, Huang Y-H, Witkiewicz A et al (2008) Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells. Cancer Bio Ther 7:1584–1590
Shrestha A, McClane BA (2013) Human claudin-8 and -14 are receptors capable of conveying the cytotoxic effects of Clostridium perfringens enterotoxin. MBio. doi:10.1128/mBio.00594-12
Shrestha A, Uzal FA, McClane BA (2016) The interaction of Clostridium perfringens enterotoxin with receptor claudins. Anaerobe 41:18–26. doi:10.1016/j.anaerobe.2016.04.011
Sierig G, Cywes C, Wessels MR, Ashbaugh CD (2003) Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect Immun 71:446–455
Singh R, Bandyopadhyay D (2007) MUC1: a target molecule for cancer therapy. Cancer Biol Ther 6:481–486
Singh U, Van Itallie CM, Mitic LL et al (2000) CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J Biol Chem 275:18407–18417
Smaldone MC, Davies BJ (2010) BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 12:607–616
Smedley JG, Uzal FA, McClane BA (2007) Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect Immun 75:2381–2390
Sorin V, Ohana P, Gallula J et al (2012) H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. ISRN Oncol 2012:351750. doi:10.5402/2012/351750
Sorin V, Ohana P, Mizrahi A et al (2011) Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. Int J Oncol 39:1407–1412
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480. doi:10.1038/nrc2394
Strumberg D, Schultheis B, Traugott U et al (2012) Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 50:76–78
Takala H, Saarnio J, Wiik H, Soini Y (2007) Claudins 1, 3, 4, 5 and 7 in esophageal cancer: loss of claudin 3 and 4 expression is associated with metastatic behavior. APMIS Acta Pathol Microbiol Immunol Scand 115:838–847
Tholey RM, Lal S, Jimbo M et al (2015) MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer. Mol Cancer Res 13:439–448. doi:10.1158/1541-7786.MCR-14-0199
Thorburn A, Thorburn J, Frankel AE (2004) Induction of apoptosis by tumor cell-targeted toxins. Apoptosis 9:19–25. doi:10.1023/B:APPT.0000012118.95548.88
Tsukita S, Furuse M (2000) Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol 149:13–16
Walther W, Petkov S, Kuvardina ON et al (2011a) Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther 19:494–503. doi:10.1038/gt.2011.136
Walther W, Schlag PM, Stein U (2011b) Local gene delivery for therapy of solid tumors. Drug delivery in oncology. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 1391–1413
Walther W, Stein U (1999) Therapeutic genes for cancer gene therapy. Mol Biotechnol 13:21–28. doi:10.1385/MB:13:1:21
Walther W, Stein U Walther W, Stein U (2000) Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60:249–271. jourlib.org. http://www.jourlib.org/references/5588026. Accessed 30 Sep 2015
Winter JM, Tang LH, Klimstra DS et al (2012) A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS ONE 7:e40157. doi:10.1371/journal.pone.0040157
Yamaizumi M, Mekada E, Uchida T et al (1978) One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell. Cell 15:245–250. doi:10.1016/0092-8674(78)90099-5
Yang WS, Park S-O, Yoon A-R et al (2006) Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther 5:1610–1619. doi:10.1158/1535-7163.MCT-05-0515
Zarogoulidis P, Darwiche K, Sakkas A et al (2013) Suicide gene therapy for cancer—current strategies. J Genet Syndr gene Ther 9(4pii):16849. doi:10.4172/2157-7412.1000139
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Pahle, J., Walther, W. (2016). Bacterial Toxins for Oncoleaking Suicidal Cancer Gene Therapy. In: Walther, W. (eds) Current Strategies in Cancer Gene Therapy. Recent Results in Cancer Research, vol 209. Springer, Cham. https://doi.org/10.1007/978-3-319-42934-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-42934-2_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42932-8
Online ISBN: 978-3-319-42934-2
eBook Packages: MedicineMedicine (R0)